Related Experiment Video
Updated: Jul 29, 2025
Magnetic Isolation of Microglial Cells from Neonate Mouse for Primary Cell Cultures
Published on: July 25, 2022
Remifentanil does not affect human microglial immune activation in response to pro-inflammatory cytokines
Cinzia Dello Russo1,2, Natalia Cappoli1, Elisabetta Tabolacci3
1Dipartimento di Sicurezza e Bioetica, Sezione di Farmacologia, Università Cattolica Del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Abstract:
Remifentanil is a potent ultra-short acting μ-opioid analgesic drug, frequently used in anaesthesia due to its favorable pharmacodynamic and pharmacokinetic profile. It may be associated with the occurrence of hyperalgesia. Preclinical studies suggest a potential role of microglia, although the molecular mechanisms have not been fully elucidated. Considering the role of microglia in brain inflammation and the relevant differences among species, the effects of remifentanil were studied on the human microglial C20 cells. The drug was tested at clinically relevant concentrations under basal and inflammatory conditions. In the C20 cells, the expression and secretion of interleukin 6, interleukin 8 and the monocyte chemotactic protein 1 were rapidly induced by a mixture of pro-inflammatory cytokines. This stimulatory effect was sustained up to 24 h. Remifentanil did not exert any toxic effect nor modify the production of these inflammatory mediators, thus suggesting the lack of direct immune modulatory actions on human microglia.
Insights
Remifentanil, an anesthetic, did not directly affect human microglia immune responses. Studies on human microglial C20 cells show no immune modulation by this potent opioid analgesic.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Remifentanil is a short-acting opioid analgesic used in anesthesia.
- Opioid-induced hyperalgesia is a concern, with potential involvement of microglia.
- Molecular mechanisms linking remifentanil and microglial activation remain unclear.
Purpose of the Study:
- To investigate the direct effects of remifentanil on human microglial cells.
- To determine if remifentanil modulates inflammatory mediator production in microglia.
Main Methods:
- Human microglial C20 cells were treated with remifentanil at clinical concentrations.
- Cells were studied under basal and pro-inflammatory cytokine-stimulated conditions.
- Expression and secretion of IL-6, IL-8, and MCP-1 were measured.
Main Results:
- Pro-inflammatory cytokines rapidly induced IL-6, IL-8, and MCP-1 in C20 cells.
- This inflammatory response was sustained for up to 24 hours.
- Remifentanil did not exhibit toxicity or alter the production of these inflammatory mediators.
Conclusions:
- Remifentanil does not appear to have direct immune-modulatory effects on human microglia.
- The study suggests that remifentanil's potential role in hyperalgesia may not involve direct microglial activation.
- Further research is needed to elucidate the mechanisms of remifentanil-induced hyperalgesia.
